Takeshi Nagasaka
Overview
Explore the profile of Takeshi Nagasaka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
3419
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kimura K, Katata Y, Umeda Y, Tanaka T, Yano S, Yoshida K, et al.
Oncol Lett
. 2024 Jul;
28(3):439.
PMID: 39081965
The present study investigated the role of ramucirumab (RAM) in treating liver metastases (LMs) as a second-line or salvage treatment in patients with advanced CRC. Of the 36 patients, 21...
2.
Yasui K, Toshima T, Inada R, Umeda Y, Yano S, Tanioka H, et al.
Mol Cancer
. 2024 Jan;
23(1):1.
PMID: 38172877
This study investigates methylation patterns in circulating cell-free DNA (ccfDNA) for their potential role in colorectal cancer (CRC) detection and the monitoring of treatment response. Through methylation microarrays and quantitative...
3.
Tanioka H, Okawaki M, Yano S, Yoshimitsu T, Tokuda K, Nyuya A, et al.
Oncol Lett
. 2023 Feb;
25(3):98.
PMID: 36817039
The neutrophil-to-lymphocyte ratio (NLR) is a well-known prognostic biomarker for patients with gastric cancer (GC). However, for patients with GC treated with palliative chemotherapy, the predictive values of NLR remain...
4.
Toshima T, Tanioka H, Mori Y, Tanaka T, Yasui K, Kimura K, et al.
Oncology
. 2022 Oct;
101(2):105-116.
PMID: 36244328
Introduction: Gastric cancer is divided into four subtypes by their molecular features linked with genetic alterations, e.g., Epstein-Barr virus (EBV), microsatellite instability-high (MSI-high), chromosomal instability (CIN), and genomically stable (GS),...
5.
Watanabe J, Maeda H, Nagasaka T, Yokota M, Hirata K, Akazawa N, et al.
Int J Cancer
. 2022 Jun;
151(12):2172-2181.
PMID: 35723084
This multicenter single-arm, phase II study evaluated the efficacy and safety of uninterrupted panitumumab usage combined with cytotoxic doublets for unresectable/metastatic colorectal cancer (mCRC). Additionally, clinical value of the RAS/BRAF...
6.
Inada R, Nagasaka T, Shimokawa M, Ojima H, Noura S, Tanioka H, et al.
Eur J Cancer
. 2022 May;
169:166-178.
PMID: 35569283
Background: An optimal treatment strategy using oxaliplatin and bevacizumab for metastatic colorectal cancer has not been defined. We investigated whether the sequential treatment using fluoropyrimidines with bevacizumab followed by the...
7.
Matsuda A, Yamada T, Takahashi T, Hirata K, Nagasaka T, Ishimaru K, et al.
J Anus Rectum Colon
. 2022 Feb;
6(1):52-57.
PMID: 35128137
Background: Anti-epidermal growth factor receptor (EGFR) therapy has been identified to prolong the survival of metastatic colorectal cancer (mCRC) patients without mutations. However, its efficacy is not always consistent for...
8.
Yamaguchi Y, Katata Y, Sano F, Tanioka H, Okawaki M, Yamamura M, et al.
Mol Clin Oncol
. 2021 Dec;
16(1):20.
PMID: 34881040
[This corrects the article DOI: 10.3892/mco.2020.2125.].
9.
Taniguchi F, Nyuya A, Toshima T, Yasui K, Mori Y, Okawaki M, et al.
Future Sci OA
. 2021 Nov;
7(10):FSO757.
PMID: 34840814
Aim: To evaluate whether PCR-reverse sequence-specific oligonucleotide can examine the concordance between liquid biopsy and metastatic lesions with acquired resistance. Materials & Methods: We examined acquired mutations in chemoresistant lesions...
10.
Umeda Y, Nagasaka T, Takagi K, Yoshida R, Yoshida K, Fuji T, et al.
Langenbecks Arch Surg
. 2021 Nov;
407(2):685-697.
PMID: 34839388
Background: To aid in the oncological management of multiple bilobar colorectal liver metastases (CRLMs), we describe a new surgical procedure, VEssel-Skeletonized PArenchyma-sparing Hepatectomy (VESPAH). Study Design: Of 152 patients with...